128 related articles for article (PubMed ID: 38567846)
1. Lusutrombopag as a Repurposing Drug in Combination with Aminoglycosides against Vancomycin-Resistant Enterococcus.
She P; Li L; Yang Y; Zhou L; Huang G; Xiao D; Wu Y
ACS Infect Dis; 2024 Apr; 10(4):1327-1338. PubMed ID: 38567846
[TBL] [Abstract][Full Text] [Related]
2. Library Screening for Synergistic Combinations of FDA-Approved Drugs and Metabolites with Vancomycin against VanA-Type Vancomycin-Resistant Enterococcus faecium.
Gargvanshi S; Gutheil WG
Microbiol Spectr; 2022 Oct; 10(5):e0141222. PubMed ID: 35969069
[TBL] [Abstract][Full Text] [Related]
3. Repurposing of the Tamoxifen Metabolites to Treat Methicillin-Resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococcus faecalis Infections.
Miró-Canturri A; Vila-Domínguez A; Caretero-Ledesma M; Ayerbe-Algaba R; Pachón J; Jiménez-Mejías ME; Smani Y
Microbiol Spectr; 2021 Oct; 9(2):e0040321. PubMed ID: 34668743
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.
Wu T; Meyer K; Harrington AT; Danziger LH; Wenzler E
J Antimicrob Chemother; 2019 May; 74(5):1300-1305. PubMed ID: 30753495
[TBL] [Abstract][Full Text] [Related]
5. [In vitro susceptibility of Enterococcus strains to high level aminoglycosides and heavy metals].
Nakipoğlu Y; Gümüş D; Sertel Selale D; Küçüker MA
Mikrobiyol Bul; 2009 Oct; 43(4):545-51. PubMed ID: 20084907
[TBL] [Abstract][Full Text] [Related]
6. Repurposing niclosamide for intestinal decolonization of vancomycin-resistant enterococci.
Mohammad H; AbdelKhalek A; Abutaleb NS; Seleem MN
Int J Antimicrob Agents; 2018 Jun; 51(6):897-904. PubMed ID: 29432868
[TBL] [Abstract][Full Text] [Related]
7. Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci.
AbdelKhalek A; Abutaleb NS; Elmagarmid KA; Seleem MN
Sci Rep; 2018 May; 8(1):8353. PubMed ID: 29844350
[TBL] [Abstract][Full Text] [Related]
8. Repurposing 9-Aminoacridine as an Adjuvant Enhances the Antimicrobial Effects of Rifampin against Multidrug-Resistant Klebsiella pneumoniae.
She P; Li Y; Li Z; Liu S; Yang Y; Li L; Zhou L; Wu Y
Microbiol Spectr; 2023 Jun; 11(3):e0447422. PubMed ID: 37036368
[TBL] [Abstract][Full Text] [Related]
9. Virulence profiles of vancomycin-resistant enterococci isolated from surface and ground water utilized by humans in the North West Province, South Africa: a public health perspective.
Matlou DP; Bissong MEA; Tchatchouang CK; Adem MR; Foka FET; Kumar A; Ateba CN
Environ Sci Pollut Res Int; 2019 May; 26(15):15105-15114. PubMed ID: 30924038
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin-resistant enterococci.
Rubinstein E; Keynan Y
Crit Care Clin; 2013 Oct; 29(4):841-52. PubMed ID: 24094380
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of vancomycin-resistant enterococci in the United Arab Emirates: a retrospective analysis of 12 years of national AMR surveillance data.
Thomsen J; Abdulrazzak NM; AlRand H; ; Menezes GA; Moubareck CA; Everett DB; Senok A; Podbielski A
Front Public Health; 2023; 11():1275778. PubMed ID: 38089023
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial resistance profile of Enterococcus species isolated from intestinal tracts of hospitalized patients in Jimma, Ethiopia.
Abamecha A; Wondafrash B; Abdissa A
BMC Res Notes; 2015 Jun; 8():213. PubMed ID: 26036911
[TBL] [Abstract][Full Text] [Related]
13. High incidence of virulence determinants, aminoglycoside and vancomycin resistance in enterococci isolated from hospitalized patients in Northwest Iran.
Haghi F; Lohrasbi V; Zeighami H
BMC Infect Dis; 2019 Aug; 19(1):744. PubMed ID: 31455296
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial Activity of an FtsZ Inhibitor Celastrol and Its Synergistic Effect with Vancomycin against Enterococci
Lu X; Wang Y; Guo W; Zhang Z; Hu X; Nie T; Yang X; Li C; Wang X; Li X; Lu Y; Li G; Zhang Y; Sun L; Pang J; You X
Microbiol Spectr; 2023 Feb; 11(1):e0369922. PubMed ID: 36622182
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019-2020 Nationwide Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).
Tsai HY; Lee YL; Liu PY; Lu MC; Shao PL; Lu PL; Cheng SH; Ko WC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Lee WS; Shi ZY; Chen YS; Wang FD; Tseng SH; Chen YH; Sheng WH; Lee CM; Chen YH; Liao CH; Hsueh PR
Int J Antimicrob Agents; 2021 Jul; 58(1):106353. PubMed ID: 33961991
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activities of teichomycin and vancomycin alone and in combination with rifampin and aminoglycosides against staphylococci and enterococci.
Tuazon CU; Miller H
Antimicrob Agents Chemother; 1984 Apr; 25(4):411-2. PubMed ID: 6233934
[TBL] [Abstract][Full Text] [Related]
17. Emergence of High-level Gentamicin Resistance among
Labibzadeh M; Kaydani GA; Savari M; Ekrami A
Pol J Microbiol; 2018; 67(4):401-406. PubMed ID: 30550226
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the in vitro activity of levofloxacin and other antimicrobial agents against vancomycin-susceptible and vancomycin-resistant Enterococcus species.
Hayden MK; Matushek MG; Trenholme GM
Diagn Microbiol Infect Dis; 1995 Aug; 22(4):349-52. PubMed ID: 8582142
[TBL] [Abstract][Full Text] [Related]
19. In vitro Antimicrobial Activity of Fosfomycin, Rifampin, Vancomycin, Daptomycin Alone and in Combination Against Vancomycin-Resistant
Tong J; Jiang Y; Xu H; Jin X; Zhang L; Ying S; Yu W; Qiu Y
Drug Des Devel Ther; 2021; 15():3049-3055. PubMed ID: 34285472
[TBL] [Abstract][Full Text] [Related]
20. In-vitro activities of 11 antibiotics against vancomycin-resistant enterococci isolated in Japan.
Miyazaki S; Ishii Y; Ohno A; Furuya N; Matsumoto T; Tateda K; Yamaguchi K
J Antimicrob Chemother; 1999 Sep; 44(3):415-6. PubMed ID: 10511414
[No Abstract] [Full Text] [Related]
[Next] [New Search]
